These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6084549)

  • 1. Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice.
    Zaharko DS; Covey JM
    Cancer Treat Rep; 1984 Oct; 68(10):1255-64. PubMed ID: 6084549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental chemotherapy (L1210) with 5-aza-2'-deoxycytidine in combination with pyran copolymer (MVE-4), an immune adjuvant.
    Zaharko DS; Covey JM; Muneses CC
    J Natl Cancer Inst; 1985 Jun; 74(6):1319-24. PubMed ID: 2582176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice.
    Covey JM; Zaharko DS
    Eur J Cancer Clin Oncol; 1985 Jan; 21(1):109-17. PubMed ID: 2578963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitro.
    Covey JM; Zaharko DS
    Cancer Treat Rep; 1984 Dec; 68(12):1475-81. PubMed ID: 6210141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological concepts and the combination of cyclophosphamide with 5-aza-2'-deoxycytidine on L1210 in vivo.
    Zaharko DS
    J Immunopharmacol; 1985; 7(2):195-202. PubMed ID: 2411821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of 5-aza-2'-deoxycytidine antileukemic activity by concomitant treatment with cytarabine.
    Colombo T; Rossi C; D'Incalci M
    Cancer Treat Rep; 1986 Dec; 70(12):1451-3. PubMed ID: 2431776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
    Chabot GG; Momparler RL
    Cancer Treat Rep; 1984 Dec; 68(12):1483-7. PubMed ID: 6210142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific potentiation of L1210 vaccine by pyran copolymer.
    Mohr SJ; Chirigos MA; Smith GT; Fuhrman FS
    Cancer Res; 1976 Jun; 36(6):2035-9. PubMed ID: 1268855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side chain of the drug.
    Zunino F; Pratesi G; Pezzoni G
    Cancer Treat Rep; 1987 Apr; 71(4):367-73. PubMed ID: 3829013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
    Presant CA; Valeriote F; Vietti TJ
    Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the alpha-D-anomer of 5-aza-2'-deoxycytidine on L1210 mouse leukemic cells in vitro and in vivo.
    Veselý J; Pískala A
    Cancer Res; 1984 Nov; 44(11):5165-8. PubMed ID: 6207913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
    Neil GL; Berger AE; Bhuyan BK; DeSante DC
    Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia.
    Momparier RL; Gonzales FA
    Cancer Res; 1978 Sep; 38(9):2673-8. PubMed ID: 79443
    [No Abstract]   [Full Text] [Related]  

  • 16. Incorporation of a potent antileukemic agent, 5-aza-2'-deoxycytidine, into DNA of cells from leukemic mice.
    Veselý J; Cihák A
    Cancer Res; 1977 Oct; 37(10):3684-9. PubMed ID: 71199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
    Momparler RL; Momparler LF
    Cancer Chemother Pharmacol; 1989; 25(1):51-4. PubMed ID: 2480188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage involvement in the protective effect of pyran copolymer against the Madison lung carcinoma (M109).
    Schultz RM; Papamatheakis JD; Luetzeler J; Ruiz P; Chirigos MA
    Cancer Res; 1977 Feb; 37(2):358-64. PubMed ID: 832262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells.
    Momparler RL; Veselý J; Momparler LF; Rivard GE
    Cancer Res; 1979 Oct; 39(10):3822-7. PubMed ID: 476619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical and biological adjuvants capable of potentiating tumor cell vaccine.
    Chirigos MA; Stylos WA; Schultz RM; Fullen JR
    Cancer Res; 1978 Apr; 38(4):1085-91. PubMed ID: 416906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.